{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:20:46Z","timestamp":1790742046976,"version":"4.1.0"},"reference-count":26,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,10,30]],"date-time":"2022-10-30T00:00:00Z","timestamp":1667088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: Despite an intensive multimodal treatment approach, approximately 50% of high-risk (HR) neuroblastoma (NB) patients experience progression. Despite the advances in targeted therapy, high-dose chemotherapy, and other systemic treatment options, radiation therapy (RT) to sites of relapsed disease can be an option to reduce tumor burden and improve chance for disease control. Methods: Patients who received salvage irradiation with proton beam therapy (PBT) for local or metastatic relapse of HR NB within the prospective registry trials KiProReg and ProReg were eligible for this retrospective analysis. Data on patient characteristics, multimodality therapy, adverse events, and oncologic endpoints were evaluated. Adverse events were assessed before, during, and after PBT according to common terminology criteria for adverse events (CTCAE) V4.0. Results: Between September 2013 and September 2020, twenty (11 male; 9 female) consecutive patients experiencing local (N = 9) or distant recurrence (N = 25) were identified for this analysis. Distant recurrences included osteomedullary (N = 11) or CNS lesions (N = 14). Salvage therapy consisted of re-induction chemo- or chemo-immuno-therapy (N = 19), surgery (N = 6), high-dose chemotherapy and stem cell transplantation (N = 13), radiation (N = 20), and concurrent systemic therapy. Systemic therapy concurrent to RT was given to six patients and included temozolomide (N = 4), carboplatine (N = 1), or anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKI) (N = 1). A median dose of 36 Gy was applied to the 34 recurrent sites. Local RT was applied to 15 patients, while five patients, received craniospinal irradiation for CNS relapse. After a median follow-up (FU) of 20 months (4\u201366), the estimated rate for local control, distant metastatic free survival, and overall survival at 3 years was 68.0%, 37.9%, and 61.6%, respectively. During RT, ten patients (50%) presented with a higher-grade acute hematologic adverse event. Late higher-grade sequelae included transient myelitis with transverse section (N = 2) and secondary malignancy outside of the RT field (N = 1). Conclusion: Our study demonstrates the efficacy and safety of RT\/PBT for recurrent HR NB in a multimodality second-line approach. To better define the role of RT for these patients, prospective studies would be desirable.<\/jats:p>","DOI":"10.3390\/curroncol29110649","type":"journal-article","created":{"date-parts":[[2022,10,30]],"date-time":"2022-10-30T10:47:57Z","timestamp":1667126877000},"page":"8222-8234","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and Feasibility of Proton Beam Therapy in Relapsed High-Risk Neuroblastoma-Experiences from the Prospective KiProReg Registry"],"prefix":"10.3390","volume":"29","author":[{"given":"Danny","family":"Jazmati","sequence":"first","affiliation":[{"name":"Department of Particle Therapy, University Hospital Essen, West German Proton Therapy Centre Essen (WPE), West German Cancer Center (WTZ), 45147 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Hero","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital, University of Cologne, 50937 Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa M.","family":"Thole.-Kliesch","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology\/Hematology, Charit\u00e9-Universit\u00e4tsmedizin, 10117 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Merta","sequence":"additional","affiliation":[{"name":"Department of Particle Therapy, University Hospital Essen, West German Proton Therapy Centre Essen (WPE), West German Cancer Center (WTZ), 45147 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6115-4893","authenticated-orcid":false,"given":"Hedwig E.","family":"Deubzer","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology\/Hematology, Charit\u00e9-Universit\u00e4tsmedizin, 10117 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0512-1146","authenticated-orcid":false,"given":"Christian","family":"B\u00e4umer","sequence":"additional","affiliation":[{"name":"West German Proton Therapy Centre Essen (WPE), West German Cancer Center (WTZ), 45147 Essen, Germany"},{"name":"Department of Physics, TU Dortmund University, 44227 Dortmund, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feline","family":"Heinzelmann","sequence":"additional","affiliation":[{"name":"West German Proton Therapy Centre Essen (WPE), West German Cancer Center (WTZ), 45147 Essen, Germany"},{"name":"Department of Physics, TU Dortmund University, 44227 Dortmund, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie Schulze","family":"Schleithoff","sequence":"additional","affiliation":[{"name":"Department of Particle Therapy, University Hospital Essen, West German Proton Therapy Centre Essen (WPE), West German Cancer Center (WTZ), 45147 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Koerber","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Cologne, 50937 Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3476-8184","authenticated-orcid":false,"given":"Angelika","family":"Eggert","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology\/Hematology, Charit\u00e9-Universit\u00e4tsmedizin, 10117 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Schwarz","sequence":"additional","affiliation":[{"name":"Department of RT and Radiooncology, Outpatient Center, University Medical Center Hamburg-Eppendorf, Martinistra\u00dfe 52, 20246, 20251 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3425-8451","authenticated-orcid":false,"given":"Thorsten","family":"Simon","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital, University of Cologne, 50937 Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Timmermann","sequence":"additional","affiliation":[{"name":"Department of Particle Therapy, University Hospital Essen, West German Proton Therapy Centre Essen (WPE), West German Cancer Center (WTZ), 45147 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Van Arendonk, K., and Chung, D. (2019). Neuroblastoma: Tumor Biology and Its Implications for Staging and Treatment. Children, 6.","DOI":"10.3390\/children6010012"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejca.2019.09.025","article-title":"Neuroblastoma between 1990 and 2014 in the Netherlands: Increased incidence and improved survival of high-risk neuroblastoma","volume":"124","author":"Tas","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejca.2018.12.032","article-title":"A systematic review of re-induction chemotherapy for children with relapsed high-risk neuroblastoma","volume":"111","author":"Herd","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1016\/j.ejca.2009.06.010","article-title":"Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry","volume":"45","author":"Garaventa","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1002\/cncr.30934","article-title":"Historical time to disease progression and progression-free survival in patients with recurrent\/refractory neuroblastoma treated in the modern era on Children\u2019s Oncology Group early-phase trials","volume":"123","author":"London","year":"2017","journal-title":"Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"112818","DOI":"10.1016\/j.ejmech.2020.112818","article-title":"Development of differentiation modulators and targeted agents for treating neuroblastoma","volume":"207","author":"Jin","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.bbmt.2017.12.805","article-title":"Haploidentical Stem Cell Transplantation for Refractory\/Relapsed Neuroblastoma","volume":"24","author":"Illhardt","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/S1470-2045(21)00536-2","article-title":"Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: An open-label, multicentre, phase 1, dose-escalation and dose-expansion study","volume":"22","author":"Fischer","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.ijrobp.2011.08.035","article-title":"Proton Radiotherapy for High-Risk Pediatric Neuroblastoma: Early Outcomes and Dose Comparison","volume":"83","author":"Hattangadi","year":"2012","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.radonc.2008.06.012","article-title":"Abdominal cancer during early childhood: A dosimetric comparison of proton beams to standard and advanced photon radiotherapy","volume":"89","author":"Hillbrand","year":"2008","journal-title":"Radiother. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"580","DOI":"10.3109\/0284186X.2012.705892","article-title":"A model for the relative biological effectiveness of protons: The tissue specific parameter \u03b1\/\u03b2 of photons is a predictor for the sensitivity to LET changes","volume":"52","author":"Wedenberg","year":"2012","journal-title":"Acta Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1200\/JCO.20.00203","article-title":"Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children\u2019s Oncology Group","volume":"38","author":"Mody","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e27408","DOI":"10.1002\/pbc.27408","article-title":"Managing local-regional failure in children with high-risk neuroblastoma: A single institution experience","volume":"65","author":"Dove","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jpedsurg.2010.09.068","article-title":"Local control, survival, and operative morbidity and mortality after re-resection, and intraoperative radiation therapy for recurrent or persistent primary high-risk neuroblastoma","volume":"46","author":"Rich","year":"2011","journal-title":"J. Pediatr. Surg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2020.10.020","article-title":"Central nervous system relapse in high-risk stage 4 neuroblastoma: The HR-NBL1\/SIOPEN trial experience","volume":"144","author":"Berlanga","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/cncr.11448","article-title":"Central nervous system metastases in neuroblastoma","volume":"98","author":"Matthay","year":"2003","journal-title":"Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1002\/1097-0142(19911101)68:9<1999::AID-CNCR2820680926>3.0.CO;2-0","article-title":"Primary extracranial neuroblastoma with central nervous system metastases characterization by clinicopathologic findings and neuroimaging","volume":"68","author":"Kellie","year":"1991","journal-title":"Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.ijrobp.2009.09.005","article-title":"Whole Neuraxis Irradiation to Address Central Nervous System Relapse in High-Risk Neuroblastoma","volume":"78","author":"Croog","year":"2010","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejca.2013.08.012","article-title":"Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: A European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study","volume":"50","author":"Devos","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5259","DOI":"10.1200\/JCO.2006.06.1572","article-title":"Phase II Study of Temozolomide in Relapsed or Refractory High-Risk Neuroblastoma: A Joint Soci\u00e9t\u00e9 Fran\u00e7aise des Cancers de l\u2019Enfant and United Kingdom Children Cancer Study Group\u2013New Agents Group Study","volume":"24","author":"Rubie","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_22","unstructured":"(2022, January 12). Targeting ALK in Neuroblastoma\u2014Preclinical and Clinical Advancements | Nature Reviews Clinical Oncology n.d. Available online: https:\/\/www.nature.com\/articles\/nrclinonc.2012.72."},{"key":"ref_23","first-page":"159","article-title":"Radiotherapy and Tyrosine Kinase Inhibitors in Stage IV Non-small Cell Lung Cancer: Real-life Experience","volume":"32","author":"Borghetti","year":"2018","journal-title":"Vivo"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.ijrobp.2013.11.010","article-title":"Stereotactic Radiation Therapy can Safely and Durably Control Sites of Extra-Central Nervous System Oligoprogressive Disease in Anaplastic Lymphoma Kinase-Positive Lung Cancer Patients Receiving Crizotinib","volume":"88","author":"Gan","year":"2014","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Jazmati, D., Butzer, S., Hero, B., Khalil, D.A., Merta, J., B\u00e4umer, C., Plum, G., Fuchs, J., Koerber, F., and Steinmeier, T. (2021). Proton Beam Therapy for Children With Neuroblastoma: Experiences From the Prospective KiProReg Registry. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.617506"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e26732","DOI":"10.1002\/pbc.26732","article-title":"Transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: A case series","volume":"65","author":"Ding","year":"2017","journal-title":"Pediatr. Blood Cancer"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/11\/649\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:06:20Z","timestamp":1760144780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/11\/649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,30]]},"references-count":26,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["curroncol29110649"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29110649","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,30]]}}}